Vascular receptors as new substrates for matrix metalloproteinases in hypertension and other inflammatory states.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

1. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2023
   Review
2. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis.Hypertension (Dallas, Tex. : 1979) · 2015
   Review
3. Cardiac ischemia and ischemia/reperfusion cause wide proteolysis of the coronary endothelial luminal membrane: possible dysfunctions.The open cardiovascular medicine journal · 2011
   Article

Corrections and comments

• Comment on
  Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.2010

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as